Yale University Purchases Sequenom MassARRAY Platform

SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced the purchase by the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University of Sequenom’s MassARRAY^® system. Yale plans to use the system as a platform for genotyping, copy number variation (CNV), methylation and quantitative gene expression (QGE) applications.

“The W.M. Keck Foundation Biotechnology Resource Laboratory is a highly respected institution, making this a particularly important placement,” said Mike Monko, SEQUENOM’S Senior Vice President, Sales and Marketing. “The MassARRAY system’s ability to provide multiple applications for genetic research on a single platform has promoted the placement of our platform into almost all major university core laboratories.”

Shrikant M. Mane, Ph.D., Director of Microarray Resources at the W.M. Keck Facility, stated, “Service requests from Yale researchers as well as other third-party organizations have significantly increased, prompting our purchasing decision. After conducting a thorough analysis of competing platforms in the gene- and whole-genome and fine-mapping and validation genetic analysis markets, we chose Sequenom's MassARRAY technology as the platform that best suits our numerous requirements.”

About Sequenom

Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, livestock and agricultural applications, molecular medicine, and noninvasive prenatal testing. Sequenom’s proprietary MassARRAY system is a high-performance nucleic acid analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. Sequenom has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms.

Sequenom^® and MassARRAY^® are trademarks of Sequenom, Inc.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Yale’s planned use of the Company’s MassARRAY system, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s operating performance, demand for and market acceptance of the Company’s products, services, and technologies, new technology and product development and commercialization particularly for new technologies such as molecular diagnostics, and particularly noninvasive prenatal diagnostics, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s SEC (U.S. Securities and Exchange Commission) filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2007 and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.